Skip to main content

Table 2 Baseline values and LSM changes from baseline at week 12

From: Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs

PROBaseline value, mean ± SDLSM change from baseline (95% CI)
PlaceboUpadacitinib 15 mgUpadacitinib 30 mgPlaceboUpadacitinib 15 mgUpadacitinib 30 mg
PtGA66.3 ± 22.7 (n = 166)67.2 ± 19.6 (n = 163)64.7 ± 21.1 (n = 163)− 10.03 (− 14.22, − 5.84) (n = 145)− 26.04* (− 30.16, − 21.93) (n = 156)− 29.27* (− 33.43, − 25.12) (n = 147)
Pain VAS68.9 ± 21.0 (n = 166)68.2 ± 19.8 (n = 163)65.3 ± 20.7 (n = 161)− 10.38 (− 14.60, − 6.16) (n = 145)− 25.91* (− 30.05, − 21.76) (n = 156)− 30.92* (− 35.12, − 26.72) (n = 146)
HAQ-DI1.6 ± 0.6 (n = 166)1.7 ± 0.6 (n = 163)1.6 ± 0.6 (n = 161)− 0.16 (− 0.25, − 0.08) (n = 145)− 0.41* (− 0.50, − 0.33) (n = 156)− 0.44* (− 0.52, − 0.35) (n = 146)
SF-36 PCS31.6 ± 7.2 (n = 166)30.6 ± 7.8 (n = 163)31.5 ± 7.3 (n = 162)2.39 (1.14, 3.64) (n = 145)5.83* (4.60, 7.05) (n = 156)7.02* (5.78, 8.25) (n = 147)
SF-36 MCS45.9 ± 12.6 (n = 166)44.0 ± 11.7 (n = 163)45.9 ± 12.3 (n = 162)3.01 (1.65, 4.37) (n = 145)4.54 (3.22, 5.87) (n = 156)3.37 (2.03, 4.72) (n = 147)
SF-36 PF32.0 ± 8.9 (n = 166)30.6 ± 9.3 (n = 163)31.2 ± 8.1 (n = 162)1.54 (0.25, 2.84) (n = 145)4.56* (3.29, 5.83) (n = 156)6.15* (4.87, 7.43) (n = 147)
SF-36 RP34.2 ± 8.0 (n = 166)33.0 ± 8.8 (n = 163)34.9 ± 7.6 (n = 162)2.15 (0.95, 3.35) (n = 145)5.10* (3.93, 6.27) (n = 156)5.17* (3.99, 6.36) (n = 147)
SF-36 BP33.2 (6.4) (n = 166)33.1 (6.4) (n = 163)34.5 (6.9) (n = 162)4.71 (3.38, 6.04) (n = 145)8.12* (6.82, 9.42) (n = 156)9.09* (7.78, 10.41) (n = 147)
SF-36 GH38.9 ± 9.7 (n = 166)37.1 ± 8.2 (n = 163)38.1 ± 9.1 (n = 162)2.17 (1.01, 3.34) (n = 145)4.31** (3.17, 5.45) (n = 156)4.25*** (3.10, 5.41) (n = 147)
SF-36 VT40.6 ± 9.3 (n = 166)37.7 ± 10.0 (n = 163)39.2 ± 9.4 (n = 162)3.10 (1.69, 4.51) (n = 145)6.28* (4.90, 7.65) (n = 156)6.86* (5.47, 8.26) (n = 147)
SF-36 SF39.5 ± 10.9 (n = 166)37.3 ± 10.4 (n = 163)39.1 ± 10.8 (n = 162)3.45 (2.10, 4.81) (n = 145)5.87*** (4.55, 7.19) (n = 156)5.35*** (4.01, 6.69) (n = 147)
SF-36 RE41.0 ± 12.6
(n = 166)
39.2 ± 12.7 (n = 163)41.5 ± 12.8 (n = 162)2.66 (1.24, 4.07) (n = 145)4.72*** (3.34, 6.10) (n = 156)3.78 (2.38, 5.17) (n = 147)
SF-36 MH43.6 ± 12.5
(n = 166)
42.9 ± 11.3 (n = 163)44.2 ± 11.4 (n = 162)2.96 (1.63, 4.29) (n = 145)3.83 (2.53, 5.12) (n = 156)3.53 (2.21, 4.84) (n = 147)
AM stiffness duration, minutes138.4 ± 178.6
(n = 169)
140.4 ± 189.7
(n = 164)
184.5 ± 284.9
(n = 165)
− 15.07 (− 43.30, 13.16) (n = 147)− 81.47* (− 109.52, − 53.42) (n = 157)− 79.13* (− 107.26, − 51.00) (n = 148)
AM stiffness severity6.8 ± 2.3 (n = 169)6.8 ± 2.1 (n = 164)6.5 ± 2.2 (n = 165)− 1.57 (− 1.98, − 1.17) (n = 146)− 2.86* (− 3.26, − 2.46) (n = 157)− 3.22* (− 3.62, − 2.82) (n = 147)
ISI12.3 ± 6.9 (n = 153)12.3 ± 6.9 (n = 152)12.3 ± 6.6 (n = 151)− 1.69 (− 2.55, − 0.83) (n = 130)− 2.53 (− 3.36, − 1.70) (n = 142)− 3.32** (− 4.15, − 2.49) (n = 138)
EQ-5D-5L49.7 ± 24.9 (n = 166)50.7 ± 23.0 (n = 163)51.8 ± 21.8 (n = 160)7.45 (3.86, 11.04) (n = 145)15.03** (11.55, 18.51) (n = 156)15.12** (11.55, 18.69) (n = 145)
  1. AM morning, BP bodily pain, CI confidence interval, EQ-5D-5L Euro Qol 5-Dimension 5-Level Questionnaire, GH general health, HAQ-DI Health Assessment Questionnaire Disability Index, LSM least squares mean, MCS Mental Component Summary, MH mental health, PCS Physical Component Summary, PF physical functioning, PRO patient-reported outcome, PtGA Patient Global Assessment of Disease Activity, RE role-emotional, RP role-physical, SD standard deviation, SF social functioning, SF-36 Short Form-36 Health Survey, VAS visual analog scale, VT vitality
  2. *P ≤ 0.001 for upadacitinib vs placebo
  3. **P < 0.01 for upadacitinib vs placebo
  4. ***P < 0.05 for upadacitinib vs placebo